Italia markets open in 5 hours 19 minutes

OSE Immunotherapeutics SA (0RAD.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
6,94+0,69 (+11,09%)
Alla chiusura: 05:49PM GMT
Schermo intero
Chiusura precedente6,25
Aperto0,00
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume664
Media VolumeN/D
Capitalizzazione924.656
Beta (5 anni mensile)1,20
Rapporto PE (ttm)N/D
EPS (ttm)-0,93
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer

    NANTES, France, July 13, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately. Alexis Vandier brings an impressive track record of successes in Pharma across a range of international roles and therapeutic areas, including oncology. Dr. Dominique Costantini, Chairwoman of the Board, said: “The Board of Directors is very pleased to announce Alexis Vandier as OSE

  • GlobeNewswire

    OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder’s Meeting

    NANTES, France, June 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors. The results of each resolution voted on can be found on the Company’s website in the “Investor – General Shareholders’ Meeting” section: https://ose-immuno.com/en/general-shareholders-meetings/. In total, the sh

  • GlobeNewswire

    OSE Immunotherapeutics Announces Collaboration with Microsoft

    OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech event.This collaboration will give OSE the opportunity to further develop its digital tools and infrastructures, particularly in terms of Artificial Intelligence and algorithmic approaches applied to the development of innovative first-in-class immunotherapies. NANTES, France, June 16, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: